DGX — Quest Diagnostics Incorporated

Is DGX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Neutral As of October 3, 2026

Quest Diagnostics Incorporated (DGX) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Diagnostics & Research) last closed at $233.33. The rating moved from Oversold to Neutral on October 3, 2026.

AI analysis

Quest Diagnostics is positioned as a large, diversified diagnostics provider with resilient cash generation, scale-driven margins and an expanding molecular/precision testing portfolio that supports medium-term growth. Defensive sector flows and recent insider activity add near-term support, while automation and targeted M&A can enhance profitability. Key headwinds include reimbursement and payer-design pressures, competitive threats from other national and decentralized testing providers, and execution/regulatory risks that could weigh on volumes and pricing. Given current market caution, expect measured upside driven by new test adoption and efficiency gains, tempered by policy and payer developments.

Key factors

  • Large national lab footprint and integrated diagnostics network providing stable scale advantages and broad payer access
  • Diverse revenue mix with recurring clinical testing volumes and growing molecular/precision diagnostics offerings
  • Solid cash flow generation enabling dividends, share repurchases and targeted M&A to extend service lines
  • Operational efficiency and automation initiatives that support margin expansion and unit-cost reductions
  • Recent insider Form 4 signal interpreted positively by the market as alignment with shareholder value
  • Defensive sector positioning that tends to out-perform in risk-off market environments, supporting near-term resilience
  • Pipeline of new tests, partnerships and hospital/health-system contracts that could drive organic growth and higher-margin services

Risks

  • Reimbursement pressure from Medicare pricing policy and broader payer negotiations that could compress revenue and margins
  • Medicare Advantage plan design changes and payer cost-control initiatives that may alter testing utilization and pricing dynamics
  • Competition from LabCorp, hospital/in-house labs, point-of-care testing and emerging decentralized diagnostics entrants
  • Regulatory, compliance and litigation risk inherent to lab operations and novel diagnostics commercialization
  • Supply-chain disruptions or equipment shortages that could constrain throughput or increase operating costs
  • Macroeconomic and market risk that can limit capital markets access and weigh on elective testing volumes
  • Execution risk on new test rollouts, integration of acquisitions and maintenance of quality metrics

See today's live rating, score and targets

Members see the live hourly rating for DGX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.